What Is The Investigation About? On March 27, 2025, BLCO disclosed that it had " [egun] to see an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with enVista® ...

On March 27, 2025, BLCO disclosed that it had “ [begun] to see an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with enVista® intraocular lenses (IOLs ...

On March 27, 2025, Bausch + Lomb announced a voluntary recall of intraocular lenses on its enVista platform due to reports of toxic anterior segment syndrome, a potential complication in cataract ...

On March 27, 2025, BLCO disclosed that it had “ [begun] to see an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with enVista® intraocular lenses (IOLs ...

As Healio previously reported, Bausch + Lomb voluntarily recalled the enVista platform due to reports of toxic anterior segment syndrome in patients implanted with the IOLs in the U.S.

After a thorough investigation in collaboration with a globally recognized toxic anterior segment syndrome (TASS) expert and an advisory group of nearly 30 top cataract surgeons including American ...

The Vaughan, Ontario-based company said last month that it initiated a voluntary recall of the IOLs following reports of an unexplained increase in cases of toxic anterior segment syndrome (TASS).

After a thorough investigation in collaboration with a globally recognized toxic anterior segment syndrome (TASS) expert and an advisory group of nearly 30 top cataract surgeons including American ...

Bausch + Lomb Corporation issued a recall for multiple models of eye implants in its enVista platform after "an increased number of reports of toxic anterior segment syndrome (TASS)," per the recall.

Bausch + Lomb issued the recall after the company received reports of toxic anterior segment syndrome, or an inflammatory reaction inside the eye.

The recall was issued in response to reports of toxic anterior segment syndrome, or TASS, an acute sterile anterior chamber inflammatory reaction that usually develops 12 to 48 hours after surgery.